211 related articles for article (PubMed ID: 19229530)
21. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
[TBL] [Abstract][Full Text] [Related]
22. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
23. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
24. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.
Almeida L; Vaz-da-Silva M; Silveira P; Falcão A; Maia J; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
Clin Neuropharmacol; 2004; 27(1):17-24. PubMed ID: 15090932
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
LeWitt PA; Jennings D; Lyons KE; Pahwa R; Rabinowicz AL; Wang J; Guarnieri M; Hubble JP; Murck H
Mov Disord; 2009 Jul; 24(9):1319-24. PubMed ID: 19412946
[TBL] [Abstract][Full Text] [Related]
28. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
29. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
Ahtila S; Kaakkola S; Gordin A; Korpela K; Heinävaara S; Karlsson M; Wikberg T; Tuomainen P; Männistö PT
Clin Neuropharmacol; 1995 Feb; 18(1):46-57. PubMed ID: 8665534
[TBL] [Abstract][Full Text] [Related]
30. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
[TBL] [Abstract][Full Text] [Related]
32. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
Trenkwalder C; Kuoppamäki M; Vahteristo M; Müller T; Ellmén J
Neurology; 2019 Mar; 92(13):e1487-e1496. PubMed ID: 30824559
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Othman AA; Dutta S
Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
[TBL] [Abstract][Full Text] [Related]
34. Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.
Tuunainen J; Sjöstedt N; Vahteristo M; Ellmén J; Kuoppamäki M; Rouru J; Yliperttula M
Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):23-34. PubMed ID: 36309950
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Woitalla D
Mov Disord; 2006 Mar; 21(3):332-6. PubMed ID: 16211593
[TBL] [Abstract][Full Text] [Related]
36. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Giladi N; Gurevich T; Djaldetti R; Adar L; Case R; Leibman-Barak S; Sasson N; Caraco Y
Parkinsonism Relat Disord; 2021 Oct; 91():139-145. PubMed ID: 34619438
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
[TBL] [Abstract][Full Text] [Related]
38. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Ruottinen HM; Rinne UK
Clin Neuropharmacol; 1996 Jun; 19(3):222-33. PubMed ID: 8726541
[TBL] [Abstract][Full Text] [Related]
39. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
40. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
